Status:
UNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Colorectal Cancer
Microsatellite Instability
Eligibility:
All Genders
Brief Summary
MSI (Microsatellite Instability) colorectal cancer (CRC) show improved survival, are less prone to metastasis and show poor response to chemotherapy (compared to MSS tumors). The underlying reasons fo...
Detailed Description
WP1 - To identify exon/intron junctions that are specifically affected by aberrant splicing events in MSI CRC. Sequences will first be evaluated at CNG using Illumina's Pipeline CASAVA (Consensus Asse...
Eligibility Criteria
Inclusion
- All patients presenting a MSI CRC (second or third state, histologically confirmed) who have been operated at Saint Antoine Hospital between 1998 and 2013
- Clinical data of patients follow-up available on site
- non-opposition for tumour samples using from patient obtained
Exclusion
- non-opposition for tumour samples using from patient not obtained
Key Trial Info
Start Date :
April 5 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2021
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT03447431
Start Date
April 5 2018
End Date
February 1 2021
Last Update
July 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'Anatomie et de Cytologie Pathologique
Paris, France, 75012